PPARA and metabolic dysfunction-associated steatotic liver disease: Additionally, other PPAR agonists are being investigated for the treatment of MASLD in phase 2 (saroglitazar—PPARα/γ dual agonist and chiglitazar—PPARα/δ/γ pan agonist) and phase 3 studies (lanifibranor—PPARα/δ/γ pan agonist) [54].